[Molecular forms of PSA and differentiating between benign hypertrophy,carcinoma, and disseminated prostatic carcinoma. Correlation between two determination technics]. / Formas moleculares de PSA en la discriminación entre hipertrofia benigna, carcinoma y carcinoma diseminado de próstata. Correlación entre dos diferentes técnicas de determinación.

OBJECTIVE: To determine the correlation between two methods of measurement of total PSA (PSA-T) and free PSA (PSA-F) and the utility of the PSA-F/PSA-T ratio in patients with PSA-T between 4 and 10 ng/ml suspected as having prostate cancer. METHODS: Determinations of both PSA-T and PSA-F were performed using two different techniques in 91 patients suspected as having prostate cancer. Diagnosis was made on the findings of biopsy and the complementary tests. RESULTS: The following correlation was found for the two techniques: R = 0.99 and p < 0.05 for PSA-T, and R = 0.85 and p < 0.05 for PSA-F. For PSA-T values of 4-10 ng/ml and PSA-F greater than 25%, we found two patients with prostate cancer. For a PSA-F/PSA-T ratio less than 9%, all cases had prostate cancer. Three cases with bone metastasis had PSA-T values less than 10 ng/ml. CONCLUSIONS: A PSA-F/PSA-T ratio greater than 25% does not exclude malignancy in patients with a total PSA of 4-10 ng/ml; values less than 9% correspond to prostate cancer. Bone metastasis was found with both methods in patients with total PSA values less than 10 ng/ml.

[Incidence of neoplasms in non-congenital refractory anemias. Ferrokinetic pattern]. / Incidencia de neoplasias en anemias refractarias no congénitas. Patrón ferrocinético.

Twenty cases of refractory anemia were studied by means of ferrokinetic analysis with Fe-59. An accelerated plasma clearing, a diminished iron uptake by red cells, and a decreased bone marrow activity were found. Half of the cases showed secondary liver and spleen hemochromatosis. The incidence of malignant tumors observed in the studied refractory anemias was 35% (7 out of 20 cases, corresponding to 4 solid tumors and 3 leukemias). The authors suggest the convenience to study erythropoiesis in anemias with an obscure origin using the ferrokinetic procedure with Fe-59.

[Isotopic scanning in the diagnosis of bone metastases of breast cancer. Comparative study with radiologic and clinical observations]. / El rastreo isotópico en el diagnóstico de las metástasis oseas del cáncer de mama. Estudio comparativo con la radiología y la clínica.

A group of 122 breast cancer patients, 42 of them with bone metastases are studied, and the role of the radioisotopic whole body scanning and the serial skeletal radiography are considered.

[Metabolic curietherapy with P-32 in bone metastases in breast cancer]. / Curieterapia metabólica con P-32 en las metástasis óseas del cáncer de mama.

The administration of radioactive phosphorus (P-32) for the treatment of pain in metastatic bone lesions from breast cancer shows palliative effects lasting three to nine months. The evolution of the disease is not modified.